CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 12 enrolled
Drug / intervention
prednisone +1 moredrug
Likely dose
Prednisone 20 mg orally once daily for 2 weeksAI-extracted
Key inclusion· 2
  • ✓Meets DSM-IV criteria for PTSD with symptom exacerbation (CAPS score ≥50)
  • ✓Stable on other psychotropic medications for at least 1 month
Key exclusion· 5
  • ✕Current or past history of bipolar disorder, schizophrenia, or other psychotic disorder
  • ✕Organic mental disorder
  • ✕Alcohol or substance abuse in the last 3 months
  • ✕Clinically significant hepatic or renal disease or other acute or unstable medical condition

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00204737
NCT00204737Phase 4Completed
CompareCT.gov

A Placebo-controlled, Randomized, Double-blind Comparison of Placebo vs Short Course Low Dose Corticosteroids on Posttraumatic Stress Disorder (PTSD)

University of Wisconsin, Madison·interventional·Posted Sep 20, 2005·Updated May 6, 2020

In Brief

A Phase 4 clinical trial evaluating prednisone and placebo for Post-traumatic Stress Disorder. Completed, enrolled 12 participants across 2 sites.

Detailed Summary

The purpose of this study is to investigate if a 2-wk course of 20mg/day of oral prednisone in addition to standard care will result in reduced PTSD symptoms or symptom severity compared to placebo

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPost-traumatic Stress Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 20, 2005
Enrollment StartDec 1, 2004
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 20.8 years ago

Interventions

prednisonedrug

20mg x 2 weeks

placebodrug

placebo